Allergy Therapeutics plc (AIM: AGY) has pioneered an ultra-short course allergy treatment (typically acute hayfever), Pollinex Quattro, which in the financial year ending June 2017 year generated revenues in excess of £64m mostly in Europe.
The ability to deliver a disease-modifying outcome as opposed to simply symptomatic relief, with short/ultrashort course treatments significantly differentiates Pollinex Quattro from its competitors.
AGY has established a significant market share in the European market, achieving double-digit compound annual revenue growth over the past 18 years. AGY is seeking to roll out Pollinex Quattro in the US, which has an estimated US$2bn market. To date 15 clinical trials have been completed, including phase I, II & III.
As at 30 June 2018 AGY had a cash balance of £15.5m.
To visit Allergy Therapeutics website, click here
Manuel Llobet (CEO)
Joined 2009. Previously CEO of International Operations of the Weinstein family’s group of companies.
Nick Wykeman (FD)
Ex Group Financial Controller of Skyepharma. Held same role at Quest International (part of ICI PLC)
Peter Jensen (NE Chairman)
21yrs with SmithKline Beecham. Previously NED of several listed businesses.
NED’s – Thomas Lander (25 yrs R&D in pharma), Stephen Smith (management accountant), Jeff Barton (VP licensing & acquisitions, Abbott)
Allergy Therapeutics plc (LON:AGY) today released Preliminary Results for the year ended 30th June 2018. European market share for their …
Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce the successful …
Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces a placing and subscription …
Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update …
AIM Listed Allergy Therapeutics (LON:AGY) has received positive data from a study on the long-lasting efficacy of Pollinex Quattro Grass, …
AIM-listed Allergy Therapeutics has today released positive new data from its house-dust mite immunotherapy. This data will be displayed today …
|Cost of Sales||(16,771)||(14,070)|
|Profit Before Tax/ (Loss)||(1,970)||(12,064)|
|Cash & cash equivalents||22,122||23,406|
ALK (OMX: ALKB)
Grass & ragweed allergy treatment
Stallergenes (EURO: STAGR)
Grass allergy treatment
ALK Abello (CPH: ALK-B)
Research-driven pharma, focused on allergies
DBV Technologies (EPA: DBV)
Biopharmaceutical company focused on food allergies
Manuel Llobet – 0.55%
Stephen Smith – 0.13%
Peter Jensen – 0.03%
Nick Wykeman – 0.03%
Weinstein A ESQ – 40.49%
Southern Fox Investments Ltd – 21.42%
Odey Asset Management – 7.36%
Invesco AM – 5.74%
Blackrock – 5.11%
GlaxoSmithKlein PLC – 1.70%
“…the global vaccine market, in its entirety, has quadrupled in value since 2000 with the World Health Organisation estimating market growth to almost $100bn by 2025.” (Panmure Gordon note, June 2015)
“In the US, it is estimated over 80m people suffer from Allergic Rhinitis (AR), albeit with diagnosis rates which remain low at 31%.” (Panmure Gordon note, June 2015)
Shares Magazine (May 2018)
“Allergy Therapeutics grass allergy product meets primary objectives”
Thisismoney.co.uk (May 2018)
“Allergy Therapeutics shares were boosted by positive data from a phase two study for its grass allergy treatment. It paves the way for phase three trials next year. Shares ticked up 9.2 per cent, or, 2.25p to 26.75p.”
The Sunday Times (Sep 2017)
“Children allergic to peanuts could soon be offered a short course of injections to cure them of the condition. AIM-listed Allergy Therapeutics has already tested the vaccine in the laboratory, and is poised to scale up production before applying for approval from regulators. It will then begin human trials.”